SAN DIEGO, July 28, 2020 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in two
upcoming investor conferences.
Details of the company's participation are as follows:
- William Blair Biotech Focus Conference 2020
Details:
Viking management will participate in 1-on-1 meetings
Conference Date: August 4-6, 2020
Format: Virtual Conference
- BTIG Virtual Biotechnology Conference
Details: Viking
management will participate in a fireside chat and 1-on-1
meetings
Conference Date: August 10-11,
2020
Fireside Chat Time/Date: 3:30 p.m.
Eastern on Tuesday, August 11,
2020
Format: Virtual Conference
About Viking Therapeutics, Inc.
Viking Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel, orally available, first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders. Viking's research and development
activities leverage its expertise in metabolism to develop
innovative therapeutics designed to improve patients' lives.
The company's clinical programs include VK2809, a novel, orally
available, small molecule selective thyroid hormone receptor beta
agonist for the treatment of lipid and metabolic disorders, which
is currently being evaluated in a Phase 2b study for the
treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)
and fibrosis. In a Phase 2 trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company is also developing VK0214,
a novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of X-linked
adrenoleukodystrophy (X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301101410.html
SOURCE Viking Therapeutics, Inc.